Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

IPIX Innovation Pharmaceuticals Inc (PK)

-0.0001 (-1.96%)
Nov 30 2023 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 488,000
Bid Price 0.0007
Ask Price 0.079
News -
Day High 0.0053


52 Week Range


Day Low 0.0043
Company Name Stock Ticker Symbol Market Type
Innovation Pharmaceuticals Inc (PK) IPIX OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0001 -1.96% 0.005 16:30:13
Open Price Low Price High Price Close Price Prev Close
0.0043 0.0043 0.0053 0.005 0.0051
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
7 488,000 $ 0.005019 $ 2,449 - 0.0007 - 0.03
Last Trade Time Type Quantity Stock Price Currency
13:05:51 69,000 $ 0.005 USD

Innovation Pharmaceuticals Inc (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
0 514.01M 342.36M 0 -3.17M -0.01 0.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Innovation Pharmaceuticals (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No IPIX Message Board. Create One! See More Posts on IPIX Message Board See More Message Board Posts

Historical IPIX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.00380.00660.00380.0045303635,0810.001231.58%
1 Month0.00790.008950.00070.0062478469,279-0.0029-36.71%
3 Months0.0160.0180.00070.0092957436,441-0.011-68.75%
6 Months0.0170.0210.00070.0124422345,102-0.012-70.59%
1 Year0.0210.030.00070.0164698439,756-0.016-76.19%
3 Years0.1650.540.00070.15572081,202,849-0.16-96.97%
5 Years0.13750.650.00070.1784121,286,086-0.1325-96.36%

Innovation Pharmaceuticals (PK) Description

An early stage developmental biopharmaceutical company...with six pharmaceutical compound candidates that are designed for treatment of diseases which may be either existing or diseases identified in the future. The Company will initially spend most of its efforts and resources on its anti-cancer compound, Kevetrin, for the treatment of head and neck cancers.

Your Recent History

Delayed Upgrade Clock